<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sanuwave Health, Inc. — News on 6ix</title>
<link>https://6ix.com/company/sanuwave-health-inc</link>
<description>Latest news and press releases for Sanuwave Health, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 21:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sanuwave-health-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d785ad51cc36e475343480.webp</url>
<title>Sanuwave Health, Inc.</title>
<link>https://6ix.com/company/sanuwave-health-inc</link>
</image>
<item>
<title>Sanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-Year</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-reports-preliminary-q1-2026-revenue-of-dollar96-dollar97-million-up-3-4percent-year-over-year</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-reports-preliminary-q1-2026-revenue-of-dollar96-dollar97-million-up-3-4percent-year-over-year</guid>
<pubDate>Thu, 16 Apr 2026 21:00:00 GMT</pubDate>
<description>Sanuwave is pleased to announce preliminary revenues of $9.6 million to $9.7 million for the first quarter ended March 31, 2026, in line with prior guidance for Q1. EDEN PRAIRIE, Minn., April 16, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved directed energy systems used in advanced wound care, today announced that revenues for the first quarter of 2026 are expected to be in the range of $9.6 to $9.7 million, an inc</description>
</item>
<item>
<title>Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-announces-record-revenues-and-financial-results-for-q4-and-full-year-2025</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-announces-record-revenues-and-financial-results-for-q4-and-full-year-2025</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Q4 2025 revenues were $13.4 million, up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. Full year 2025 revenues were $44.1 million</description>
</item>
<item>
<title>Sanuwave Will Host a Conference Call on March 27, 2026 at 8:30 AM (ET) to Present Q4 and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-will-host-a-conference-call-on-march-27-2026-at-830-am-et-to-present-q4-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-will-host-a-conference-call-on-march-27-2026-at-830-am-et-to-present-q4-and-full-year-2025-financial-results</guid>
<pubDate>Fri, 20 Mar 2026 04:00:00 GMT</pubDate>
<description>EDEN PRAIRIE, Minn., March 20, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of</description>
</item>
<item>
<title>Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-announces-preliminary-q4-2025-revenue-of-dollar133-dollar134-million-up-29-30percent-year-over-year-achieves-record-quarterly-and-full-year-revenue</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-announces-preliminary-q4-2025-revenue-of-dollar133-dollar134-million-up-29-30percent-year-over-year-achieves-record-quarterly-and-full-year-revenue</guid>
<pubDate>Fri, 09 Jan 2026 05:00:00 GMT</pubDate>
<description>Sanuwave is pleased to announce preliminary revenues of $13.3 million to $13.4 million for the fourth quarter ended December 31, 2025. This represents the</description>
</item>
<item>
<title>Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-to-participate-in-the-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-to-participate-in-the-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Wed, 10 Dec 2025 11:00:00 GMT</pubDate>
<description>EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved next-generation wound care products, is pleased to announce that it will be attending the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA from January 12th to January 15th 2026. Those wishing to meet with company management during the conference should reach out to [email protected] to schedule a time. About</description>
</item>
<item>
<title>Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-announces-the-addition-of-ultramist-to-healogics-group-purchasing-organization-gpo-isupply</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-announces-the-addition-of-ultramist-to-healogics-group-purchasing-organization-gpo-isupply</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>Healogics Wound Care Supply adds UltraMIST to its Group Purchasing Organization Healogics iSupply and Sanuwave collaborate to provide UltraMIST as an option</description>
</item>
<item>
<title>Sanuwave Announces Q3 FY2025 Financial Results</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-announces-q3-fy2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-announces-q3-fy2025-financial-results</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>Q3 2025 revenues were $11.5 million, up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history. Q3 2025 gross</description>
</item>
<item>
<title>Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-will-host-a-conference-call-on-november-7-2025-at-830-am-et-to-present-q3-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-will-host-a-conference-call-on-november-7-2025-at-830-am-et-to-present-q3-2025-financial-results</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of</description>
</item>
<item>
<title>Sanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025)</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-announces-preliminary-revenue-results-for-the-third-quarter-2025-ended-september-30-2025</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-announces-preliminary-revenue-results-for-the-third-quarter-2025-ended-september-30-2025</guid>
<pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
<description>Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest</description>
</item>
<item>
<title>Sanuwave Announces Strategic Debt Refinancing with New Credit Facility</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-announces-strategic-debt-refinancing-with-new-credit-facility</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-announces-strategic-debt-refinancing-with-new-credit-facility</guid>
<pubDate>Fri, 26 Sep 2025 04:00:00 GMT</pubDate>
<description>Credit facility from J.P. Morgan consists of a four-year term loan of $23 million and a two-year $5 million revolving credit facility backed by accounts</description>
</item>
<item>
<title>Sanuwave Announces Q2 FY2025 Financial Results</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-announces-q2-fy2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-announces-q2-fy2025-financial-results</guid>
<pubDate>Fri, 08 Aug 2025 04:00:00 GMT</pubDate>
<description>Q2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross</description>
</item>
<item>
<title>Sanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET) to Present Q2 2025 Financial Results</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-will-host-a-conference-call-on-august-8-2025-at-830-am-et-to-present-q2-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-will-host-a-conference-call-on-august-8-2025-at-830-am-et-to-present-q2-2025-financial-results</guid>
<pubDate>Mon, 04 Aug 2025 21:00:00 GMT</pubDate>
<description>EDEN PRAIRIE, Minn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 8, 2025, at 8:30 AM (ET) to present its Q2 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID</description>
</item>
<item>
<title>Sanuwave Health to Present at Canaccord Genuity Growth Conference</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-to-present-at-canaccord-genuity-growth-conference</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-to-present-at-canaccord-genuity-growth-conference</guid>
<pubDate>Tue, 22 Jul 2025 20:05:00 GMT</pubDate>
<description>EDEN PRAIRIE, Minn., July 22, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ: SNWV), a leading provider of next-generation, FDA-approved wound care products , today announced, that Morgan Frank, Chief Executive Officer, will present at the 45th Annual Canaccord Genuity Growth Conference, being held August 12–13, 2025, at the InterContinental Hotel in Boston, Massachusetts. Sanuwave’s group presentation is scheduled for Wednesday, August 13, from 9:30 to 9:55 a.m. ET. In addition to the p</description>
</item>
<item>
<title>Sanuwave Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025)</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-announces-preliminary-revenue-results-for-the-second-quarter-2025-ended-june-30-2025</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-announces-preliminary-revenue-results-for-the-second-quarter-2025-ended-june-30-2025</guid>
<pubDate>Mon, 14 Jul 2025 04:00:00 GMT</pubDate>
<description>Sanuwave is pleased to announce preliminary revenues of $10.1 million to $10.2 million for the second quarter ended June 30, 2025. This represents the highest</description>
</item>
<item>
<title>Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-appoints-industry-veteran-dustin-libby-as-executive-vice-president-of-commercial-operations</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-appoints-industry-veteran-dustin-libby-as-executive-vice-president-of-commercial-operations</guid>
<pubDate>Tue, 03 Jun 2025 04:00:00 GMT</pubDate>
<description>Libby brings strong team building, growth, and sales operations and systems skills to Sanuwave after a career of growing startups into mid- and large-sized</description>
</item>
<item>
<title>Sanuwave Health Selected for Inclusion in Russell 2000® Index</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-selected-for-inclusion-in-russell-2000r-index</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-selected-for-inclusion-in-russell-2000r-index</guid>
<pubDate>Wed, 28 May 2025 20:10:00 GMT</pubDate>
<description>EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ: SNWV), a leading provider of next-generation, non-invasive wound care solutions, today announced, as part of the 2025 Russell indexes reconstitution, the Company’s inclusion in the Russell 2000® Index. This will be effective after the U.S. market opens on June 30. In addition to the Russell 2000® Index, the Company is also expected to be included in the broader Russell 3000® Index and in the Russell Microcap® In</description>
</item>
<item>
<title>Sanuwave Health Appoints Greg Bazar to Board of Directors</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-appoints-greg-bazar-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-appoints-greg-bazar-to-board-of-directors</guid>
<pubDate>Wed, 28 May 2025 20:05:00 GMT</pubDate>
<description>Bazar brings decades of experience in engineering, computer science and cyber security, AI, and business intelligence over a career of building successful companiesEDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (Nasdaq:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of Greg Bazar to its Board of Directors. Bazar brings decades of leadership experience in engineering, tech</description>
</item>
<item>
<title>Sanuwave Announces Q1 FY2025 Financial Results</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-announces-q1-fy2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-announces-q1-fy2025-financial-results</guid>
<pubDate>Fri, 09 May 2025 04:00:00 GMT</pubDate>
<description>Q1 2025 revenues were $9.3 million, up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 gross</description>
</item>
<item>
<title>Sanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial Results</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-will-host-a-conference-call-on-may-9-2025-at-830-am-et-to-present-q1-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-will-host-a-conference-call-on-may-9-2025-at-830-am-et-to-present-q1-2025-financial-results</guid>
<pubDate>Mon, 05 May 2025 21:00:00 GMT</pubDate>
<description>EDEN PRAIRIE, Minn., May 05, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, May 9, 2025, at 8:30 AM (ET) to present its Q1 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SA</description>
</item>
<item>
<title>SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)</title>
<link>https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-announces-preliminary-revenue-results-for-the-first-quarter-2025-ended-march-31-2025</link>
<guid isPermaLink="true">https://6ix.com/company/sanuwave-health-inc/news/sanuwave-health-announces-preliminary-revenue-results-for-the-first-quarter-2025-ended-march-31-2025</guid>
<pubDate>Tue, 08 Apr 2025 04:00:00 GMT</pubDate>
<description>SANUWAVE is pleased to announce preliminary revenues of $9.1 million to $9.3 million for the first quarter ended March 31, 2025. This represents the highest</description>
</item>
</channel>
</rss>